Lexington, MA – July 18, 2017 – Shire plc (LSE: SHP, NASDAQ: SHPG), the biotech leader in Rare Diseases; and Novimmune S.A., a privately-held Swiss biopharmaceutical company focused on the discovery and development of innovative, antibody-based medicines today announced they have entered into an agreement granting Shire exclusive worldwide rights to develop and commercialize an innovative, bi-specific antibody in pre-clinical development for the treatment of hemophilia A and hemophilia A patients with inhibitors. Shire is leading the development of the program to optimize and evaluate a fully-human, bi-specific IgG antibody targeting FIXa and FX, designed to imitate the body’s natural mechanism of Factor VIII-driven coagulation. The company’s ultimate aim is to deliver a treatment that improves upon the strong and long-term record of efficacy and safety that has been set by the Factor class.
“This novel program builds on our extensive monoclonal antibody (MAb) capabilities, as well as on our in-depth scientific expertise in hematology,” said Fritz Scheiflinger, Head Global Research, Shire. “While further development and clinical trials are needed to fully evaluate this antibody, we are encouraged by the potential of the data that we have seen in early discovery and the promise it may hold for hemophilia A patients and patients with inhibitors.”
Shire has been steadily building its MAb research capability, which now includes MAb programs in hereditary angioedema (HAE), diabetic macular edema, antibody-mediated autoimmune disease, and anti-thrombotic therapy—all signatures of Shire’s new Rare Diseases Innovation Center coming to Cambridge, MA.
“Novimmune is building on a collaboration initiated in 2015 with Shire to generate and evaluate Factor VIII-mimetic, bi-specific antibodies,” said Ed Holdener, Chairman and CEO of Novimmune. “We are delighted that our research efforts have produced several promising and potentially highly differentiated leads for improving coagulation in hemophilia A.”
Novimmune has been developing a platform for making fully human, bi-specific antibodies and has several in-house programs targeting tumor associated antigens and the immune system check point protein CD47.
The specific terms of this deal were not disclosed.
|Elizabeth Kalinaemail@example.com||+1 781 482 2713|
|Gwen Fisherfirstname.lastname@example.org||+1 781 482 9649|
|Ian Karpemail@example.com||+1 781 482 9018|
|Robert Coatesfirstname.lastname@example.org||+44 1256 894874|
Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.
Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.
Novimmune SA is a privately held, Swiss biopharmaceutical company focused on the discovery and development of antibody-based drugs for the targeted treatment of inflammatory diseases, immune-related disorders, and cancer. The company is headquartered in Geneva and runs a Clinical and Commercial Development Center in Basel. The company currently employs 130 people. More information is available on the company website at www.novimmune.com.
|Adrian Millsemail@example.com||+41 (0) 61 201 13 27|